XLO Stock Overview
A clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
Xilio Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.69 |
| 52 Week High | US$1.93 |
| 52 Week Low | US$0.50 |
| Beta | -0.26 |
| 1 Month Change | -31.34% |
| 3 Month Change | -30.31% |
| 1 Year Change | 15.00% |
| 3 Year Change | -94.63% |
| 5 Year Change | n/a |
| Change since IPO | -95.69% |
Recent News & Updates
Shareholder Returns
| XLO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.7% | 1.3% | 0.2% |
| 1Y | 15.0% | 0.9% | 22.0% |
Return vs Industry: XLO exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: XLO underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| XLO volatility | |
|---|---|
| XLO Average Weekly Movement | 19.7% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: XLO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: XLO's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 56 | Rene Russo | xiliotx.com |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies.
Xilio Therapeutics, Inc. Fundamentals Summary
| XLO fundamental statistics | |
|---|---|
| Market cap | US$30.45m |
| Earnings (TTM) | -US$62.80m |
| Revenue (TTM) | US$4.62m |
6.6x
P/S Ratio-0.5x
P/E RatioIs XLO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XLO income statement (TTM) | |
|---|---|
| Revenue | US$4.62m |
| Cost of Revenue | US$0 |
| Gross Profit | US$4.62m |
| Other Expenses | US$67.42m |
| Earnings | -US$62.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,359.37% |
| Debt/Equity Ratio | 0% |
How did XLO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 23:48 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xilio Therapeutics, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Schmidt | Guggenheim Securities, LLC |
| Michael Ulz | Morgan Stanley |
| Dane Leone | Raymond James & Associates |